The latest onvansertib data, and an abrupt CEO departure, spook investors.
ApexOnco Front Page
Recent articles
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
And that could affect the drug's third-line accelerated approval.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
A fresh licensing deal tidies up years of work between the two companies.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
